In addition to polymorphism, low BIM expression levels in EGFRM+ NSCLC samples may also predict poorer initial response and shorter duration of clinical benefit from EGFR-TKIs [57,212,224,225]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.